State Street
CGEM icon

State Street’s Cullinan Oncology CGEM Stock Holding History

State Street’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.8M Buy
3,668,627
+1,124,512
+44% +$16.7M ﹤0.01% 1700
2026
Q1 		$36.2M Buy
2,544,115
+346,777
+16% +$4.46M ﹤0.01% 1922
2025
Q4 		$22.7M Buy
2,197,338
+520,024
+31% +$4.69M ﹤0.01% 2187
2025
Q3 		$9.95M Buy
1,677,314
+69,722
+4% +$511K ﹤0.01% 2645
2025
Q2 		$12.1M Sell
1,607,592
-145,087
-8% -$1.17M ﹤0.01% 2476
2025
Q1 		$13.3M Sell
1,752,679
-371,805
-18% -$3.57M ﹤0.01% 2356
2024
Q4 		$25.9M Sell
2,124,484
-212,738
-9% -$3.06M ﹤0.01% 2079
2024
Q3 		$39.1M Buy
2,337,222
+396,034
+20% +$7.02M ﹤0.01% 1828
2024
Q2 		$33.9M Buy
1,941,188
+515,729
+36% +$11M ﹤0.01% 1856
2024
Q1 		$24.3M Buy
1,425,459
+860,055
+152% +$13.3M ﹤0.01% 2100
2023
Q4 		$5.76M Buy
565,404
+43,508
+8% +$385K ﹤0.01% 2880
2023
Q3 		$4.72M Sell
521,896
-325
-0.1% -$3.38K ﹤0.01% 2945
2023
Q2 		$5.62M Sell
522,221
-39,993
-7% -$425K ﹤0.01% 2940
2023
Q1 		$5.75M Buy
562,214
+7,863
+1% +$86.7K ﹤0.01% 2939
2022
Q4 		$5.85M Buy
554,351
+52,835
+11% +$642K ﹤0.01% 2975
2022
Q3 		$6.43M Buy
501,516
+27,088
+6% +$365K ﹤0.01% 2938
2022
Q2 		$6.08M Sell
474,428
-607,109
-56% -$6.88M ﹤0.01% 2993
2022
Q1 		$11.3M Sell
1,081,537
-93,826
-8% -$1.27M ﹤0.01% 2755
2021
Q4 		$18.1M Buy
1,175,363
+812,404
+224% +$16.2M ﹤0.01% 2549
2021
Q3 		$8.19M Buy
362,959
+135,116
+59% +$3.61M ﹤0.01% 2990
2021
Q2 		$5.87M Buy
227,843
+33,028
+17% +$1.02M ﹤0.01% 3176
2021
Q1 		$8.12M Buy
+194,815
New +$7.91M ﹤0.01% 2836

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's CGEM Position: Q2 2026 in Review

State Street increased its Cullinan Oncology (CGEM) stake by 44% in Q2 2026, buying an estimated $16.7M and bringing the position to 3,668,627 shares worth $66.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1700.

State Street first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • State Street held 3,668,627 shares of Cullinan Oncology worth $66.8M as of Q2 2026.
  • State Street bought 1,124,512 Cullinan Oncology shares in Q2 2026, an estimated $16.7M.
  • Cullinan Oncology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1700 holding.
  • State Street first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.